tirzepatide and cancer risk Is Linked to Cancer? FDA Safety Data Evidence Tirzepatide linked to lower risk – Possible pro-oncogenic effect of tirzepatide

Other common side effects documented in clinical trials include injection site reactions and hypoglycemia (particularly in patients taking insulin or sulfonylureas)

FDA pharmacovigilance review of FAERS reports for compounded GLP-1s has documented dosing errors, inadvertent overdoses, and product quality concerns linked specifically to the regulatory gap between compounded and brand-name product (Hoffman et al., 2025)

Websites such as GoodRx offer coupons that can reduce costs at major pharmacies (think: Walgreens, CVS, and Walmart)

2) Formulations and duration of action Vyvanse is typically designed for once daily dosing and is widely considered long-acting